Spectrum Licenses Third-Generation Taxane From Italian Firm Indena
This article was originally published in The Pink Sheet Daily
Executive Summary
The new chemical entity has demonstrated activity in taxane-refractory tumors, Spectrum said.
You may also be interested in...
ODAC Backs Delay In Orplatna Approval, Says Yes To Evista As Breast Cancer Preventative
Data is insufficient to support accelerated approval of GPC Biotech’s prostate cancer drug, FDA advisory panel says.
GPC Aims To Complete Satraplatin NDA In January, Despite Arbitration With Licensor Spectrum
Spectrum is seeking $12 million GPC was paid by sublicensee Pharmion.
Forest Files Memantine/Donepezil Fixed Combination For Alzheimer’s
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.